Article
Medicine, General & Internal
Piotr Lacina, Aleksandra Butrym, Eliza Turlej, Martyna Stachowicz-Suhs, Joanna Wietrzyk, Grzegorz Mazur, Katarzyna Bogunia-Kubik
Summary: This study confirms the importance of BSG/MCT1 in AML, and suggests that soluble BSG and BSG/MCT1 genetic variants may act as potential AML biomarkers.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Nickolas Stabellini, Benjamin Tomlinson, Jennifer Cullen, John Shanahan, Kristin Waite, Alberto J. J. Montero, Jill S. S. Barnholtz-Sloan, Nelson Hamerschlak
Summary: This study conducted a comprehensive analysis of sex differences in acute myeloid leukemia (AML) and found that there are disparities in incidence and survival between males and females. Treatment and healthcare factors have important implications for survival rates.
Article
Oncology
Yue Hou, Jie Zi, Zheng Ge
Summary: The study revealed that increased RhoF expression in AML patients is associated with poor prognosis, especially in younger age groups, those receiving intensive chemotherapy, and patients without transplantation. High RhoF expression is closely related to older age, intermediate/poor-risk cytogenetics, and mutations in several genes.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to poor response to therapy or relapse, which can be attributed to the over-expression of multidrug resistance (MDR) proteins. ABCG2, an efflux transporter responsible for inducing MDR in leukemic cells, has the ability to extrude many antineoplastic drugs, leading to AML resistance and/or relapse. This review focuses on the expression and role of ABCG2, as well as its regulation and potential inhibition to counteract drug resistance and improve outcomes in AML patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jiamian Zheng, Dan Qiu, Xuan Jiang, Yun Zhao, Haotian Zhao, Xiaofang Wu, Jie Chen, Jing Lai, Wenbin Zhang, Xutong Li, Yangqiu Li, Xiuli Wu, Zhenyi Jin
Summary: This study found that an increase in the PD-1(+)Foxp3(+) gamma delta T cell subset in AML is associated with poor clinical outcome, providing predictive value for the study of AML patients.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Article
Oncology
Nabin Khanal, Valerie Shostrom, Prajwal Dhakal, Shristi Upadhyay Banskota, Chakra Chaulagain, Fiona He, Kailash Mosalpuria, Krishna Gundabolu, Vijaya Raj Bhatt
Summary: The study used NCDB to analyze factors affecting 10-year overall survival in AML patients, finding that age, gender, subtype, income, insurance type, etc. may influence survival rate. The results demonstrate poor long-term OS even among younger patients, highlighting disparities in leukemia care based on insurance type.
LEUKEMIA & LYMPHOMA
(2022)
Article
Multidisciplinary Sciences
Benedicte Sjo Tislevoll, Monica Hellesoy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Duran, Laure Piechaczyk, Dagim Shiferaw Tadele, Jorn Skavland, Baliakas Panagiotis, Randi Hovland, Vibeke Andresen, Ole Morten Seternes, Tor Henrik Anderson Tvedt, Nima Aghaeepour, Sonia Gavasso, Kimmo Porkka, Inge Jonassen, Yngvar Floisand, Jorrit Enserink, Nello Blaser, Bjorn Tore Gjertsen
Summary: In this study, the initial signaling response to standard induction chemotherapy in 32 acute myeloid leukemia (AML) patients was investigated using 36-dimensional mass cytometry. The reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy was found to be a significant predictor of patient 5-year overall survival in this cohort. This study demonstrates the value of mass cytometry in early response evaluation in AML and highlights the potential of functional signaling analyses in precision oncology diagnostics.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Xueting Kong, Jiamian Zheng, Xiaxin Liu, Wandi Wang, Xuan Jiang, Jie Chen, Jing Lai, Zhenyi Jin, Xiuli Wu
Summary: This study investigated the distribution and clonality of TRGV subfamilies in gamma delta T cells of patients with acute myeloid leukemia (AML). The expression frequencies and gene expression levels of three TRGV subfamilies in AML samples were significantly lower than those in healthy individuals (HIs). Additionally, higher expression levels of the TRGV gene and higher proportion of V gamma 9(+) V delta 2(+) T cells showed better overall survival (OS) in AML patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yu Liu, Ruyue Zheng, Yajun Liu, Lu Yang, Tao Li, Yafei Li, Zhongxing Jiang, Yanfang Liu, Chong Wang, Shujuan Wang
Summary: Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with improved outcomes through children-like regimens and novel agents; Factors affecting prognosis include age, white blood cell count, and genetic abnormalities; A prognostic model has been developed to predict overall survival in newly diagnosed ALL patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Kelly J. Norsworthy, Xin Gao, Chia-Wen Ko, E. Dianne Pulte, Jiaxi Zhou, Yutao Gong, Yuan Li Shen, Jonathon Vallejo, Thomas E. Gwise, Rajeshwari Sridhara, Albert B. Deisseroth, Ann T. Farrell, R. Angelo de Claro, Gideon M. Blumenthal, Richard Pazdur
Summary: The study explores the associations between response and survival outcomes in newly diagnosed acute myeloid leukemia (AML) patients undergoing intensive chemotherapy. The analysis reveals a moderate association between complete remission (CR) rate and overall survival (OS), and a strong association between event-free survival (EFS) and OS. However, the confidence intervals are wide, and the results became moderate when using alternative definitions for EFS. Patient-level analysis shows that CR responders have better OS compared to CRi or CRp responders and nonresponders.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Adrian Mosquera Orgueira, Andres Peleteiro Raindo, Jose angel Diaz Arias, Beatriz Antelo Rodriguez, Monica Lopez Rinon, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia Gonzalez Perez, Giovanni Martinelli, Pau Montesinos Fernandez, Manuel Mateo Perez Encinas
Summary: The Stellae-123 gene expression signature has shown high accuracy in predicting prognosis of AML patients, particularly those with high-risk mutations. The signature's prognostic performance is reproducible in external cohorts and superior to other scoring systems for predicting patient survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Review
Biochemistry & Molecular Biology
Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian
Summary: While mechanistic studies have shed light on the molecular mechanisms of AML and led to the development of new targeted therapies, resistance remains a significant issue in AML treatment. The exploration of circRNA in AML biology and therapy resistance shows promise in providing new insights and potential solutions to managing this disease.
Review
Biochemistry & Molecular Biology
Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)